Centessa Pharmaceuticals PLC ADR (CNTA)

NASDAQ
5.17
+0.30(+6.16%)
After Hours
5.17
0.00(0.00%)
- Real-time Data
  • Volume:
    90,914
  • Day's Range:
    4.92 - 5.46
  • 52 wk Range:
    2.88 - 25.98

CNTA Overview

Prev. Close
4.87
Day's Range
4.92-5.46
Revenue
-
Open
4.92
52 wk Range
2.88-25.98
EPS
-2.48
Volume
90,914
Market Cap
486.19M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
301,160
P/E Ratio
-
Beta
-
1-Year Change
-76.63%
Shares Outstanding
94,041,029
Next Earnings Date
Aug 15, 2022
What is your sentiment on Centessa Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Centessa Pharmaceuticals PLC ADR News

Centessa Pharmaceuticals PLC ADR Company Profile

Centessa Pharmaceuticals PLC ADR Company Profile

Employees
90

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsSellSellStrong BuyStrong BuyStrong Sell
SummaryNeutralNeutralStrong BuyBuyStrong Sell